Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
Baxter
Farmers Insurance
Cerilliant
McKinsey
Healthtrust
Fish and Richardson
Citi
Merck

Generated: June 22, 2018

DrugPatentWatch Database Preview

ZYDUS PHARMS USA INC Company Profile

« Back to Dashboard

What is the competitive landscape for ZYDUS PHARMS USA INC, and what generic alternatives to ZYDUS PHARMS USA INC drugs are available?

ZYDUS PHARMS USA INC has one hundred and forty-four approved drugs.

There is one US patent protecting ZYDUS PHARMS USA INC drugs. There are eight tentative approvals on ZYDUS PHARMS USA INC drugs.

There are two patent family members on ZYDUS PHARMS USA INC drugs in two countries and one hundred and eighty-eight supplementary protection certificates in twelve countries.

Summary for ZYDUS PHARMS USA INC
International Patents:2
US Patents:1
Tradenames:124
Ingredients:124
NDAs:144

Drugs and US Patents for ZYDUS PHARMS USA INC

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Zydus Pharms Usa Inc METHYLPREDNISOLONE methylprednisolone TABLET;ORAL 206751-001 Apr 23, 2018 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Zydus Pharms Usa Inc FELBAMATE felbamate TABLET;ORAL 208970-001 May 30, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Zydus Pharms Usa Inc MEMANTINE HYDROCHLORIDE memantine hydrochloride CAPSULE, EXTENDED RELEASE;ORAL 203293-001 Aug 3, 2017 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Zydus Pharms Usa Inc ROPINIROLE HYDROCHLORIDE ropinirole hydrochloride TABLET;ORAL 090411-006 Jun 1, 2009 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Paragraph IV (Patent) Challenges for ZYDUS PHARMS USA INC drugs
Drugname Dosage Strength Tradename Submissiondate
➤ Subscribe Delayed-release Tablets 20 mg ➤ Subscribe 2015-06-03

Non-Orange Book US Patents for ZYDUS PHARMS USA INC

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,139,527 Method of preparation of pitavastatin and pharmaceutical acceptable salts thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Supplementary Protection Certificates for ZYDUS PHARMS USA INC Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
C/GB98/017 United Kingdom ➤ Try a Free Trial PRODUCT NAME: PRAMIPEXOLE, OPTIONALLY IN THE FORM OF AN ACID ADDITION SALT, IN PARTICULAR PRAMIPEXOLE DIHYDROCHLORIDE MONOHYDRATE; REGISTERED: UK EU/1/97/050/001 19971014; UK EU/1/97/050/002 19971014; UK EU/1/97/050/003 19971014; UK EU/1/97/050/004 19971014; UK EU/1/97/050/005 19971014; UK EU/1/97/050/006 19971014; UK EU/1/97/050/007 19971014; UK EU/1/97/050/008 19971014; UK EU/1/97/050/009 19971014; UK EU/1/97/050/010 19971014
0048 Netherlands ➤ Try a Free Trial PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NATL. REGISTRATION: RVG 21079 RVG 21080 19970925; FIRST REGISTRATION: PL 12619/0116 19970307
C0067 France ➤ Try a Free Trial PRODUCT NAME: AZELASTINE OU SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET UN ESTER PHARMACEUTIQUEMENT ACCEPTABLE DE FLUTICASONE; NAT. REGISTRATION NO/DATE: NL41755 20130925; FIRST REGISTRATION: SK - 24/0055/13-S 20130215
00155 Netherlands ➤ Try a Free Trial PRODUCT NAME: ESCITALOPRAM, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVA ARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER ESCITALOPRAMOXALAAT; REGISTRATION NO/DATE: RVG 30490 - RVG 30497 20040427
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Colorcon
Accenture
Moodys
Fish and Richardson
Chinese Patent Office
Cipla
Johnson and Johnson
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.